H19095 - A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab With Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with Stage I/II lymph-node negative Non-small Cell Lung Cance

Principal Investigator

Keisuke Shirai

Study Number

H19095

Summary

This is a Phase III, randomized, placebo-controlled, double-blind, multi-center study assessing the efficacy and safety of durvalumab with SoC SBRT versus placebo with SoC SBRT in patients with unresected clinical Stage I/II lymph node-negative (T1 to T3N0M0) NSCLC. An additional cohort will assess Osimertinib following SBRT in patients with early stage unresected T1 to T3N0M0 NSCLC harbouring an EGFR mutation.

Phase

I/II

Contact

Lauren Michele Robinson

Available at the following location(s)

• Lebanon

View more details at ClinicalTrials.gov

Do you need help with some of the labels on this page?
Read our glossary of terms